相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The USPTO has granted BioLife U.S. Patent 12,667,605 B2 for its effervescent oral peptide delivery technology, known internally as OralMatrix, with protection running into 2042. - Preclinical studies demonstrated measurable systemic semaglutide exposure after oral administration, providing in vivo proof of concept for the delivery platform. - Granted U.S. claims extend across the GLP-1 class, covering semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide, with international applications pending. - The technology remains in development and has not been approved for any disease, arriving as GLP-1 therapies generated roughly $132 billion in global sales in 2025.
- The FDA has allowed an Investigational New Drug (IND) application to proceed for the first-ever U.S. clinical trial of an experimental gene therapy for Mucolipidosis Type IV (MLIV), an ultra-rare inherited neurological disease affecting fewer than 100 known children worldwide. - The investigational therapy uses an AAV9 vector to deliver a functional copy of the MCOLN1 gene, aiming to restore production of the deficient mucolipin-1 protein that drives the disease. - The milestone culminates nearly a decade of Foundation-coordinated research, including preclinical work at Massachusetts General Hospital and the University of Massachusetts Gene Therapy Center. - The ML4 Foundation hopes the first children will be treated in 2026, though clinical benefit, safety, and response variability remain unknown ahead of first-in-human dosing.
- Charles River Laboratories and Medigen Vaccine Biologics (MVC) are collaborating on characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. - Charles River will apply Next-Generation Sequencing (NGS) and advanced analytical platforms to support Chemistry, Manufacturing, and Controls (CMC) activities for the vaccine program. - The partnership aims to generate robust data supporting IND applications, IND-enabling non-clinical studies, and future global clinical development. - MVC's proprietary Envacgen Enterovirus 71 Vaccine has already been approved in Taiwan and Vietnam, underscoring the company's established vaccine development capability.
- The global viral clearance market is valued at USD 1.0 billion in 2026 and is forecast to grow at a 16.9% CAGR, reaching USD 4.8 billion by 2036. - Viral removal methods, including filtration and chromatography, are projected to account for 51.0% of method demand in 2026, while recombinant proteins represent 34.0% of application demand. - FDA adoption of ICH Q5A(R2) in January 2024 has expanded risk-based viral safety validation requirements across established biologics and emerging modalities. - South Korea leads country-level growth at a 17.8% CAGR, supported by concentrated commercial biomanufacturing capacity projected to exceed 2.14 million liters by 2030.
- Charles River Laboratories raised its 2026 adjusted per-share profit forecast to $11.15–$11.45, up from the prior $10.80–$11.30, reflecting operational outperformance. - Second-quarter revenue reached $1 billion, surpassing the analyst consensus estimate of $975.7 million, with adjusted EPS of $3.02 beating the $2.74 Wall Street estimate. - CEO Birgit Girshick noted broad-based demand improvement across global biopharmaceutical and small to mid-sized biotechnology clients, particularly in drug discovery and safety assessment. - The company expects AI to generate additional drug development programs requiring validation and safety testing, though material impact may take one to two years to materialize.
- Nearly 90% of drug candidates fail in human trials due to efficacy or toxicity gaps, driving adoption of New Approach Methodologies (NAMs) including humanized mouse models, organ-on-a-chip, and AI. - Human liver-on-a-chip models achieved over 87% sensitivity and 100% specificity in predicting drug-induced liver injury, outperforming traditional animal safety screens. - AI algorithms can now screen billions of compounds in two days, but experts caution that computational speed does not guarantee clinical efficacy, citing Exscientia's failed AI-designed candidate. - The AI-accelerated nonclinical drug testing market is valued at USD 1,090.7 million in 2026 and projected to reach USD 4,489.9 million by 2036 at a 15.2% CAGR.
- The global transgenic animal model market is projected to grow from $2.79 billion in 2025 to $6.79 billion by 2035 at a CAGR of 9.2%, fueled by rising pharmaceutical R&D and genetic engineering advances. - CRISPR/Cas9 technology dominates the market with a 44.96% share in 2024, enabling rapid, precise creation of disease models for oncology, neurology, and rare genetic disorders. - Rodents, particularly mice, account for 74.96% of the animal type segment, while pharmaceutical and biotechnology companies represent 57.38% of end-user demand. - Europe's market alone is forecast to reach $2.23 billion by 2035, with Germany, the U.K., and France leading regional innovation in transgenic research.
- The UK cardiovascular clinical trials market is forecast to grow from USD 507.8 million in 2025 to USD 892.2 million by 2033, reflecting a compound annual growth rate of 7.6%. - The NHS digital infrastructure encompassing approximately 67 million patient records is a key enabler for participant recruitment and real-world evidence generation in cardiovascular trials. - Approximately 7 million people in England live with cardiovascular conditions, with cardiovascular diseases accounting for about 26% of annual deaths, underscoring the urgent need for new interventions. - Novo Nordisk's January 2026 announcement to extend cardiovascular outcome studies in the UK highlights growing industry investment in obesity-related cardiovascular risk mitigation.
- The global women's clinical trials and CRO market is projected to grow from $9.9 billion in 2026 to $22.3 billion by 2036, at a CAGR of 8.5%. - Growth is driven by rising prevalence of women-predominant conditions, regulatory requirements for sex-specific safety evaluation, and precision medicine adoption. - Decentralized trial models are accelerating enrollment; Lindus Health's hybrid trials leveraged over 30 million EHRs to double enrollment speed versus traditional approaches. - U.S.-China tariff friction is disrupting biospecimen flows and central lab operations, prompting sponsors to shift recruitment toward CRO networks in India, Southeast Asia, and Europe.
- Riaan Singh Digeorge, age 6, became the first patient worldwide to receive an experimental AAV9 gene therapy for Cockayne syndrome on April 21, 2026, at NewYork-Presbyterian Komansky Children's Hospital. - The treatment was the culmination of a nearly five-year, parent-led effort by Riaan Research Initiative, which raised nearly $4 million and fully funded every step from preclinical studies to clinical administration. - Cockayne syndrome is a severe DNA repair disorder with no FDA-approved treatments, causing brain atrophy, growth failure, and early death, with severely affected children having a life expectancy of 5 to 7 years. - The gene therapy delivers a functional ERCC8/CSA transgene via AAV9 directly to the brain; preclinical studies in mice demonstrated an 8.5-fold lifespan increase, supporting the FDA's clearance of the IND application.
